Search tips
Search criteria 


Logo of pharmscispringer.comThis journalToc AlertsSubmit OnlineOpen Choice
AAPS PharmSci. 2004 March; 6(1): 112–119.
Published online 2015 July 10. doi:  10.1208/ps060112
PMCID: PMC2750947

Encapsulation of water-insoluble drug by a cross-linking technique: Effect of process and formulation variables on encapsulation efficiency, particle size, and in vitro dissolution rate


Ibuprofen-gelatin micropellets were prepared by the cross-linking technique using formaldehyde. Spherical micropellets having an entrapment efficiency of 65% to 85% were obtained. The effect of core to coat ratio, speed of agitation, temperature, and volume of oil phase was studied with respect to entrapment efficiency, micropellet size, and surface characteristics. Fourier transform infrared spectroscopy and differential scanning calorimetric analysis confirmed the absence of any drug-polymer interaction. X-ray diffraction patterns showed that there is a decrease in crystallinity of the drug. The micromeritic properties of micropellets were found to be slightly changed by changing various processing parameters to give micropellets of good flow property. The in vitro release profile could be altered significantly by changing various processing parameters to give a controlled release of drug from the micropellets. The stability studies of the drug-loaded micropellets showed that the drug was stable at storage conditions of room temperature, 37°C, 25°/60% relative humidity (RH) and 45°/60% RH, for 12 weeks.

Keywords: ibuprofen, micropellets, gelatin micropellets


1. Goodman S, Gilman A. The Pharmacological Basis of Therapeutics. New York, NY: Macmillan Publishing Company; 1985.
2. Sellassie IG. Multiparticulate Oral Drug Delivery. New York, NY: Marcel Dekker Inc; 1994.
3. Deasy PB. Microencapsulation and Related Drug Processes. New York, NY: Marcel Dekker Inc; 1984.
4. Kondo A. Microcapsule Processing and Technology. New York, NY: Marcel Dekker Inc; 1979.
5. Sjoergen J. Rate Control in Drug Therapy. Edinburgh, UK: Churchill Livingstone; 1985.
6. Tanaka N, Takino S, Utsumi I. A new oral gelatinized sustained release dosage form. J. Pharm Sci. 1962;52:664–667. doi: 10.1002/jps.2600520714. [PubMed] [Cross Ref]
7. Kawashima Y, Niwa T, Takeuchi H, Hino T, Itoh Y, Furuyama S. Characterization of polymorphs of tranilast anhydrate and tranilast monohydrate when crystallized by two solvent change spherical crystallization techniques. J Pharm Sci. 1991;81:472–478. doi: 10.1002/jps.2600800515. [PubMed] [Cross Ref]
8. Barkai A, Pathak V, Benita S. Polyacrylate (Eudragit retard) microspheres for oral controlled release of nifedipine. I. Formulation design and process optimization. Drug Dev Ind Pharm. 1990;16:2057–2075. doi: 10.3109/03639049009023640. [Cross Ref]
9. Bodmeier R, Chen H. Preparation and characterization of microspheres containing the anti-inflammatory agents, indomethacin, ibuprofen, and ketoprofen. J Control Release. 1989;10:167–175. doi: 10.1016/0168-3659(89)90059-X. [Cross Ref]
10. Jones DS, Pearce KJ. Investigation of the effects of some process variables on, microencapsulation of propranolol HCl by solvent evaporation method. Int J Pharm. 1995;118:99–205. doi: 10.1016/0378-5173(94)00355-9. [Cross Ref]
11. Sato T, Kanke M, Schroeder G, Deluca P. Porous biodegradable microspheres for controlled drug delivery. I: Assessment of processing conditions and solvent removal techniques. Pharm Res. 1988;5:21–30. doi: 10.1023/A:1015855210319. [PubMed] [Cross Ref]
12. Wakiyama N, Juni K, Nakano M. Preparation and evaluation in vitro of polylactic acid microspheres containing local anesthetic. Chem Pharm Bull (Tokyo) 1981;29:3363–3368. doi: 10.1248/cpb.29.3363. [PubMed] [Cross Ref]

Articles from AAPS PharmSci are provided here courtesy of American Association of Pharmaceutical Scientists